Alexion initiates voluntary recall of certain lots of Soliris Alexion Pharmaceuticals announced that it is initiating a voluntary recall of certain lots of Soliris 300 mg/30 mL concentrated solution for intravenous infusion that were manufactured using a process component during vial filling identified in the November 2013 recall to the hospital/user level. As previously stated, Alexion believes that it has identified the process component that resulted in the presence of the visible particles and implemented a change to the process. Alexion does not anticipate any interruption to patient supply. This recall has been initiated due to the presence of visible proteinaceous particles detected in a single lot during periodic stability testing for Soliris. This lot was distributed only in the U.S. No safety risks to patients who have received Soliris have been identified. There is no financial impact from the voluntary recall. Following this voluntary recall, there will no longer be Soliris in the U.S. manufactured using the previously identified process component that Alexion believes resulted in the stability failure.
Alexion announces $500M share repurchase program Alexion Pharmaceuticals announced that the company’s board has authorized a new share repurchase program of up to $500M. The new share repurchase program will take effect upon completion of the company’s current program, which has approximately $22M remaining of its previously authorized $400M.